Welcome to our dedicated page for Mannkind news (Ticker: MNKD), a resource for investors and traders seeking the latest updates and insights on Mannkind stock.
MannKind Corporation reports developments across its biopharmaceutical business in cardiometabolic and orphan lung diseases. Company updates center on commercial products such as Afrezza, an inhaled insulin for diabetes, and Furoscix, a furosemide injection for fluid overload in heart failure and chronic kidney disease, as well as financial results, product demand, launch infrastructure and capital-structure actions.
MannKind news also covers dry powder inhalation programs and drug-device combinations, including work using its Technosphere platform. Recurring topics include Afrezza clinical and real-world data, Furoscix device and regulatory updates, Nintedanib DPI for idiopathic pulmonary fibrosis, ralinepag DPI collaboration activity with United Therapeutics, and other pipeline decisions affecting inhaled therapies.
MannKind (Nasdaq: MNKD) reported positive topline results from INFLO-1, its Phase 1b randomized, double-blind, placebo-controlled trial of nintedanib dry powder inhalation (DPI) in patients with idiopathic pulmonary fibrosis (IPF). The study met its primary objective, showing nintedanib DPI was generally safe and well tolerated over seven days.
Among 27 patients across 10 U.S. sites, there were no serious adverse events, no bronchospasm, no drug-related gastrointestinal side effects, and no treatment discontinuations or dose reductions. Spirometry parameters were similar between nintedanib DPI and placebo. Most patients experienced no cough, and reported cough events were mainly mild and transient. Across Phase 1a and 1b, 48 individuals (including 18 IPF patients) received nintedanib DPI, totaling more than 700 inhalations, nearly 450 in IPF. MannKind’s global Phase 2 INFLO-2 trial is actively enrolling about 210 participants at ~85 sites to further assess safety, tolerability and potential efficacy.
MannKind (Nasdaq: MNKD) announced it will report its second quarter 2026 financial results after market close on Wednesday, August 5, 2026. Management will host a conference call at 4:30 p.m. Eastern Time, with a live webcast and a replay available via the company’s investor relations website.
MannKind (Nasdaq: MNKD) has entered into a securities purchase agreement for a private placement to certain institutional investors, led by Frazier Life Sciences, with expected gross proceeds of approximately $50 million. Closing is expected on or about July 24, 2026, subject to customary conditions.
According to MannKind, the company will sell 10,440,838 common shares and pre-funded warrants for up to 2,412,632 additional shares at $3.89 per share and $3.88 per pre-funded warrant. The pre-funded warrants have a $0.01 exercise price, are exercisable after issuance subject to beneficial ownership limits, and remain outstanding until fully exercised. MannKind plans to use net proceeds for general corporate purposes, including funding a $45 million contingent value rights payment linked to FDA approval of Furoscix ReadyFlow™. The securities are unregistered and issued under Section 4(a)(2), and MannKind has agreed to file a resale registration statement with the SEC.
MannKind (Nasdaq: MNKD) announced that the FDA has approved Furoscix ReadyFlow (furosemide injection), the first and only autoinjector delivering subcutaneous furosemide with IV‑equivalent exposure for the treatment of edema in adults with heart failure or chronic kidney disease.
Furoscix ReadyFlow delivers a full 80 mg/mL furosemide dose in a single administration in under 10 seconds, compared with approximately five hours for the existing Furoscix On-body infusor. According to MannKind, the product achieved its primary pharmacokinetic endpoint and showed equivalent urine output, sodium excretion and potassium excretion at 6, 8 and 12 hours versus IV furosemide, with a safety profile consistent with oral and IV furosemide. Commercial launch in the United States is expected by the end of August 2026, targeting cardiologists, nephrologists, outpatient heart failure clinics and integrated delivery networks.
MannKind (Nasdaq: MNKD) received a Breakthrough T1D grant under the IDDP program to support the ongoing INHALE-1ST pediatric trial of Afrezza in newly diagnosed type 1 diabetes (T1D).
The multi-center study evaluates safety and efficacy of Afrezza plus basal insulin in youth 10–<18. It builds on recent FDA approval of inhaled insulin for pediatric patients 6+ and uses MannKind’s Technosphere platform. Pilot-phase enrollment is complete.
MannKind (Nasdaq: MNKD) reported new Afrezza and FUROSCIX data to be presented at the ADA 2026 Scientific Sessions. Findings cover pediatric use after recent FDA approval, gestational diabetes, use with automated insulin delivery (AID) systems, pharmacodynamic comparisons with lispro, real‑world safety, access, and heart‑failure outcomes.
Pediatric analyses from INHALE-1 showed non‑inferior HbA1c versus rapid‑acting analogs (RAA) and higher treatment satisfaction in youth achieving HbA1c <8%. Additional studies suggest comparable efficacy in gestational diabetes, earlier pharmacodynamic effect versus lispro, no increased lung cancer incidence, and lower FUROSCIX-related hospitalization rates versus standard care.
MannKind (Nasdaq: MNKD) reported key milestones for nintedanib DPI in idiopathic pulmonary fibrosis (IPF): completion of patient randomization in U.S. Phase 1b INFLO-1 and first patient enrolled in global Phase 2 INFLO-2.
Phase 1b data are expected in Q3 2026; INFLO-2 plans ~210 participants at ~85 sites worldwide, using Technosphere dry powder inhalation to deliver nintedanib directly to the lungs and potentially reduce systemic exposure.
MannKind (Nasdaq: MNKD) will host a conference call on May 29, 2026 at 4:30 p.m. Eastern to discuss the recent FDA approval of Afrezza for children and adolescents aged 6 and older with diabetes. A live webcast and 90-day replay will be available on its investor website.
MannKind (Nasdaq: MNKD) announced U.S. FDA approval of Afrezza inhaled mealtime insulin for children and adolescents aged 6 and older with type 1 and type 2 diabetes.
Afrezza offers ultra rapid-acting, needle-free dosing at the start of meals and is available to eligible patients for $35 or less per month.
MannKind (Nasdaq: MNKD) announced that CEO Michael Castagna will join a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 3 at 9:20 a.m. ET.
Live and recorded audio webcasts will be accessible for about 90 days on MannKind’s investor relations website.